FDA Advisors Want More Data On Nanotech Sunscreens
This article was originally published in The Rose Sheet
Executive Summary
Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s understanding of how pharmaceutical firms are using nanotechnology is still developing, but they maintain that currently marketed products are safe.